Literature DB >> 21556493

C-ha-ras enhances the neoplastic transformation of human breast epithelial-cells treated with chemical carcinogens.

G Calaf1, P Zhang, M Alvarado, S Estrada, J Russo.   

Abstract

The present study was carried out with the purpose of analyzing the additive effect of c-Ha-ras oncogene on tumorigenesis in human breast epithelial cells (HBEC) treated with chemical carcinogens. A human breast epithelial cell (HBEC) line, MCF-10F, previously treated with dimethylbenz(a) anthracene (DMBA) and benzo(a)pyrene (BP) was used in these studies. The MCF-10F cells, DMBA and/or BP-transformed cells originated from the clones D3-1 and BP1 which were transfected with the plasmid pH06T1 containing the human T24 mutated c-Ha-ras oncogene and termed MCF-10F-Tras, D3-1-Tras and BP1-Tras, respectively. Whereas the c-Ha-ras transfected cells presented altered morphology, increased anchorage independent growth in agar-methocel, invasiveness and tumorigenicity, the MCF-10F cells, the clones D3 and BP1 were not tumorigenic. Importantly, whereas MCF-10F-Tras was slightly tumorigenic, the D3-1-Tras and BP1-Tras transfected cells were 100% tumorigenic in the SCID mice; and the tumors thus obtained were poorly differentiated carcinomas. DNA fingerprinting confirmed that the tumors derived originated from the cell lineage used. It was concluded that c-Ha ras induces an additive effect on the expression of tumorigenesis in human breast epithelial cell line MCF-10F treated with chemical carcinogens. Our work provide a model for analyzing the role of c-Ha-ras in human breast cancer.

Entities:  

Year:  1995        PMID: 21556493     DOI: 10.3892/ijo.6.1.5

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

Review 1.  The role of the basal stem cell of the human breast in normal development and cancer.

Authors:  Jose Russo; Irma H Russo
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

2.  Ras protein expression as a marker for breast cancer.

Authors:  Gloria M Calaf; Jorge Abarca-Quinones
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.